Editor’s Note August 2, 2011

With this issue of the newly formatted Sentinel we are introducing OneMedRadio a product designed to bring our readers interviews with the CEOs and investors building some of the most innovative companies in the world of health and medicine. Our focus is on, what we call, “discovery” companies. Typically, these are firms with little or no research coverage, little visibility and are often significantly undervalued. Learn about the firms we follow.  Many of these firms are provided research coverage and will appear at the 5th Annual OneMedForum,  January 9-12th in San Francisco. Mark your calendar.  This week’s interviews:

Tim Keating who recently raised $86 million for Keating Capital discusses the broken IPO market and how firms like his and GSV Capital [NASDAQ:GSVC] are providing a way for the public to invest in high growth private companies.  Read Story…

Novadaq [TSE:NDQ – $153M MktCap]  which provides the “eyes” for the robotic surgery world is looking forward to seeing revenues ramp now that their partners Intuitive [ISRG] and Life Cell are beginning sales push, CEO Arun Menawat explains. Read story…

Jason Napodano of Zacks Investment Research who initiated research coverage on International Stem Cell Corporation [OTC: ISCO – $68M MktCap] tells OneMedRadio about this little stem cell company that seems to have found itself in the beauty business with a skin rejuvenating creme that they are now struggling to manufacture fast enough to satisfy consumers undaunted by its $150 a bottle price tag. Read story…

Also in this issue:

Bio-Rad Laboratories [NYSE:BIO]  Ligand Pharmaceuticals Inc.[NASDAQ:LGND]  GlaxoSmithKline [NYCE:GSK]  E-Therapeutics (LON:ETX). OneMedPlace announces the creation of OneMedRadio to fill research gap. Roka Bioscience raises $20 million. FDA needs to replace flawed clearance process.

The comments are closed.